AZ-ETHISPHERE
15.3.2022 11:02:14 CET | Business Wire | Press release
Ethisphere, a global leader in defining and advancing the standards of ethical business practices, today announced the 136 honorees representing 22 countries and 45 industries that have earned the coveted designation of World’s Most Ethical Companies® in 2022 .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220315005079/en/
This is the 16th annual recognition of companies that have demonstrated a commitment to ethical business practices through programs that positively impact employees, communities, and broader stakeholders, and contribute to sustainable and profitable long-term business performance.
In 2022, 14 companies are first-time honorees, while six have been recognized 16 times – every year since the inception of the awards in 2007.
“The moment is now, and the data is clear – companies must lead on sustainability, social issues, and governance. The World’s Most Ethical Companies understand that the capitalism of today and tomorrow is one that demonstrates how we turn our ideals into action,” said Ethisphere CEO, Timothy Erblich . “Congratulations to the 2022 honorees for their dedication to advancing business integrity, for leadership on tough issues, and demonstrating that doing good is key to successful, long-term performance.”
“At TIAA, transparency, accountability, and integrity are values deeply embedded in our culture,” said Thasunda Brown Duckett, President and CEO of TIAA . “We know our clients want to work with a partner they trust, and we work hard to do right by them, our employees, and our communities. We’re honored to be named one of the World’s Most Ethical Companies by Ethisphere for the eighth straight year.”
“Recognition for the 14th time as one of the World’s Most Ethical Companies is an incredible honor for which we credit our 400,000 green apron partners (employees) who show up with a common mission,” said Kevin Johnson, president and ceo, Starbucks Coffee Company. “At Starbucks, we know we have to earn the trust we have from our partners, customers, and communities each day by leading with a purpose that goes well beyond the pursuit of profit.”
“It’s a true honor to be named as one of the World’s Most Ethical Companies for the 9th consecutive year,” said Steve James, CEO of Teachers Mutual Bank Limited . “As one of only five banks across the globe to be honored this year, this recognition reinforces our credentials as a socially responsible bank seeking to make a difference. I’m proud to lead a company that is using banking as a force for good.”
Ethisphere’s 2022 Ethics Index, the collection of publicly traded companies recognized as recipients of this year’s World’s Most Ethical Companies designation, outperformed a comparable index of large-cap companies by 24.6 percentage points over the past five calendar years.
“The outperformance, which Ethisphere refers to as the Ethics Premium , has remained consistent since we began tracking the equity performance of honoree companies. We believe this outperformance is the result of the kinds of practices that lead a company to be on our list – practices that demonstrate investment in their people, culture, and communities. We see in this data that those practices, over time, lead to stronger financial performance,” Erblich added.
Ethisphere will host a Virtual Honoree Gala on April 12, 2022. It will feature keynote addresses by Matthew McConaughey, Academy Award® –winning actor, New York Times bestselling author, and founder of the just keep livin Foundation ; and Ernie Johnson , six-time Sports Emmy Award winner, and New York Times bestselling author of Unscripted: The Unpredictable Moments that Make Life Extraordinary .
Methodology & Outcomes
Grounded in Ethisphere’s proprietary Ethics Quotient® , the World’s Most Ethical Companies assessment process includes more than 200 data points on culture; environmental and social practices; ethics and compliance activities; governance; diversity, equity, and inclusion; and initiatives that support a strong value chain. The process serves as an operating framework to capture and codify the leading practices of organizations across industries and around the globe.
This year, the evaluation was updated to include questions inquiring about programmatic changes made in response to the continuing COVID-19 pandemic. It also included a new area around risk assessment, to better address the U.S. Department of Justice’s recent focus on effectiveness of a company’s risk assessment efforts; more detailed questions around key impact assessment processes; and a range of other updates to reflect the evolving landscape as it relates to those in ethics, compliance, and governance.
All companies that participate in the assessment process receive an Analytical Scorecard that provides insights into key trends among honoree companies, and where their programs stand compared to the class of honoree companies. Applicants also receive a three-month Associate membership to the Business Ethics Leadership Alliance (BELA).
Honorees
The full list of the 2022 World’s Most Ethical Companies can be found at https://worldsmostethicalcompanies.com/honorees/ .
Follow the conversation on Twitter: 2022 #WorldsMostEthicalCompanies.
About Ethisphere
Ethisphere® is the global leader in defining and advancing the standards of ethical business practices that fuel corporate character, marketplace trust, and business success. Ethisphere has deep expertise in measuring and defining core ethics standards using data-driven insights that help companies enhance corporate character and measure and improve culture. Ethisphere honors superior achievement through its World’s Most Ethical Companies recognition program and provides a community of industry experts with the Business Ethics Leadership Alliance (BELA). https://ethisphere.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005079/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
